Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18172018 | 0.88 | SCN9A (0.72) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172237 | 0.88 | SCN9A (0.72) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172235 | 0.88 | SCN9A (0.72) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172119 | 0.86 | SCN9A (1.00) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172107 | 0.85 | SCN9A (0.80) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172171 | 0.84 | SCN9A (0.78) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172191 | 0.83 | SCN9A (0.75) | SCN9ASCN5APTGS1GAAF10 | |
| SCHEMBL18172174 | 0.83 | SCN9A (0.75) | SCN9ASCN5APTGS1GAAPTGES | |
| SCHEMBL18172036 | 0.82 | SCN9A (0.55) | SCN9ASCN5APTGS1GAAPTGES | |
| SCHEMBL18172190 | 0.81 | SCN9A (0.67) | SCN9ASCN5AMAPTMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | claimed |
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-04-19 | — | — | US | disclosed |
| EP-3286178-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | Almirall S.A. (ES) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016170009-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105509-A1 | AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN7A, SCN1A, SCN1B | SCN9A 13/4885SCN5A 4/4885PTGS1 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.